Kirtland Hills Capital Management LLC Has $420,000 Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kirtland Hills Capital Management LLC lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,137 shares of the medical research company’s stock after selling 69 shares during the quarter. Kirtland Hills Capital Management LLC’s holdings in IQVIA were worth $420,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $33,000. Avior Wealth Management LLC grew its position in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. grew its position in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Concord Wealth Partners acquired a new position in shares of IQVIA in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on IQV shares. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. The Goldman Sachs Group reduced their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $251.22.

Insider Activity at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Down 1.9 %

Shares of IQV opened at $190.98 on Wednesday. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a market capitalization of $33.63 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average of $199.41 and a 200-day moving average of $215.63.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.